Programme Thesis
This programme is a peer-reviewed, open-access journal (Antimicrobial Resistance and Infection Control, ISSN 2047-2994, published by BioMed Central) that publishes research on the prevention, diagnosis, and management of antimicrobial resistance and healthcare-associated infections. It exists to disseminate high-quality evidence that can inform clinical practice and public health policy in the fight against AMR.
Selection Criteria
- Scientific validity and methodological rigor (e.g., pre-registration, appropriate controls, statistical power)
- Relevance to antimicrobial resistance and infection control (clinical, epidemiological, microbiological, or translational)
- Novelty and significance of findings (advancing the field, filling a knowledge gap)
- Adherence to reporting guidelines (e.g., STROBE, CONSORT, PRISMA) and open science practices
- Ethical compliance (e.g., patient consent, data availability)
- Clarity and quality of writing
- For a journal, acceptance is based on peer review; no explicit scoring rubric is published, but these are standard criteria for BMC journals.
Past Winners / Cohort Profiles
The page does not list specific authors or past winners. As a Q1 journal (Scimago) with an h-index of 106, typical published papers include clinical studies on infection control interventions, antimicrobial stewardship, epidemiological surveillance of resistant pathogens, and mechanistic studies of resistance. Authors are typically researchers in clinical microbiology, infectious diseases, hospital epidemiology, and public health, often from academic medical centers or public health agencies.
Ideal Candidate Fingerprint
The ideal contributor is a researcher or clinician with robust, methodologically sound data on antimicrobial resistance mechanisms, infection prevention and control strategies, or antimicrobial stewardship outcomes. They should have a clear, clinically relevant research question, use appropriate statistical or experimental methods, and provide actionable insights for reducing AMR burden. The work should be well-written, transparent, and aligned with the journal's scope.
Recommended Framing
For Eniola, the strongest angle is to submit a manuscript based on the TOPOLOGIX line, which directly addresses drug-resistance prediction using sequence-based machine learning (ESM-2 embeddings + Morgan fingerprints + Random Forest) and outperforms structure-based tools. This fits the journal's scope on antimicrobial resistance mechanisms and prediction, and leverages Eniola's computational expertise and prior work on the Platinum benchmark. Frame it as a novel, scalable approach to predicting resistance mutations that can inform surveillance and drug development, with clear methodological rigor (pre-registration, benchmark comparisons).
Watch Out
The journal is a publication venue, not a grant or fellowship; it does not provide funding. Eniola is an independent researcher without institutional affiliation, which may raise questions about data availability and ethical approvals, but his prior work and collaborations mitigate this. Also, the journal charges an APC (gold OA), which may be a financial barrier; check for waivers or discounts for LMIC authors.
Research History
2026-08-04 20:12 · medium confidence
2026-07-31 17:28 · medium confidence